Showing results (111-120 of 118) with videos related to
Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
International Journal of Clinical Oncology|October 17, 2024
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologyKazuhisa Nakashima, Ayako Yokomizo, Michiyasu Murakami, et al.International Journal of Clinical Oncology|November 21, 2024
Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical OncologyMichiyasu Murakami, Yoshiharu Miyata, Kazuhisa Nakashima, et al.International Journal of Clinical Oncology|May 9, 2024
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023Masamitsu Kobayashi, Jun Kako, Arisa Iba, et al.International Journal of Clinical Oncology|September 28, 2024
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical OncologyAyako Yokomizo, Kazuhisa Nakashima, Arisa Iba, et al.International Journal of Clinical Oncology|September 11, 2024
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncologyToshinobu Hayashi, Shun Yamamoto, Yoshiharu Miyata, et al.Journal of Cancer|October 2, 2023
Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 StudyHirotoshi Iihara, Mototsugu Shimokawa, Hiroko Bando, et al.British Journal of Cancer|November 17, 2023
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura, et al.Journal of Cancer|February 19, 2024
Proposal for Classifying the Emetogenicity of Oral Anticancer Agents with a Focus on PARP Inhibitors: A Prospective, Observational, Multicenter Study (JASCC-CINV 2002)Senri Yamamoto, Masami Tsuchiya, Hirotoshi Iihara, et al.Pageof 12